-
Ritonavir
- indication:Indicated in combination with other antiretroviral agents for the treatment of HIV-infection.
- pharmacologypharmacology:
- mechanism: Ritonavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
- toxicity: Human experience of acute overdose with ritonavir is limited. One patient in clinical trials took ritonavir 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose. The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.
- absorprion: The absolute bioavailability of ritonavir has not been determined.
- halflife: 3-5 hours
- roouteelimination:
- volumedistribution:
- clearance: